Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626024 · ClinicalTrials.gov registry record · Phase 2
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
A Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
- 4
- Study locations
NCT04626024: Recruiting Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, sponsored by Baylor College of Medicine.
NCT04626024 is a Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 100 participants, below the 207-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (52% lower). The trial reports 4 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04626024, a Phase 2 study of Chronic Myeloid Leukemia and Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
- 4
- Study locations
Study Summary
This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
Primary Outcome
The Kaplan-Meier method will be used to estimate MR free survival rate at 6 months after TKI cessation with a 95% confidence interval.
Conditions Studied
Interventions
- OTHER Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
- DRUG Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Study Locations (4)
Texas
- Baylor College of Medicine- McNair Campus - Houston
- Ben Taub General Hospital - Houston
- CHI St. Luke's Health Baylor College of Medicine Medical Center - Houston
- Harris Health System- Smith Clinic - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2020-12-22 |
| Est. Completion | 2028-11-15 |
| Phase | Phase 2 |
What NCT04626024 shows while recruiting
NCT04626024 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 207-participant average among 35 other Chronic Myeloid Leukemia trials with a reported enrollment target (52% lower).
The record links to 3 conditions, with Chronic Myeloid Leukemia appearing as the primary indexed condition, and to 2 interventions - of which Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal is the first listed.
NCT04626024 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04626024 about?
NCT04626024 is a clinical study titled "Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population". This is a single-arm, phase II study to evaluate safety and efficacy of tyrosine kinase inhibitor (TKI) cessation for chronic myeloid leukemia (CML) patients with stable molecular response in a real world population.
What is the current status of trial NCT04626024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2020-12-22. Estimated completion is 2028-11-15.
What conditions does trial NCT04626024 study?
This clinical trial studies the following conditions: Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission.
What interventions are being tested in trial NCT04626024?
The interventions under investigation include: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal (OTHER), Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation (DRUG).
Who is sponsoring clinical trial NCT04626024?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04626024 being conducted?
This trial has 4 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04626024's enrollment target sits among peer trials
100 13th of 35 higher than 23 of 35 other Chronic Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RECRUITING · Phase 2
-
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
RECRUITING · Phase 2
-
Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases
RECRUITING · Phase 2
-
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
ACTIVE NOT RECRUITING · Phase 2
-
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML
COMPLETED · Phase 2
-
Dasatinib (BMS-354835) Versus Imatinib Mesylate in Subjects With Chronic Myeloid Leukemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI